Possis asked for more information on AngioJet:
This article was originally published in Clinica
The US FDA has asked Possis Medical for more data to support its AngioJet 510(k) application. Possis submitted the thrombectomy device for peripheral applications in March (see Clinica No 696, p 22). It says it will be able to respond in about six weeks.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.